Logo image of ZEG.DE

ASTRAZENECA PLC (ZEG.DE) Stock Overview

Europe - FRA:ZEG - GB0009895292 - Common Stock

144.35 EUR
-0.35 (-0.24%)
Last: 10/17/2025, 7:00:00 PM

ZEG.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap447.56B
Revenue(TTM)56.50B
Net Income(TTM)8.29B
Shares3.10B
Float2.99B
52 Week High149.5
52 Week Low111
Yearly Dividend2.56
Dividend Yield1.95%
EPS(TTM)7.56
PE19.09
Fwd PE15.91
Earnings (Next)11-06 2025-11-06/bmo
IPO2007-09-21
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ZEG.DE short term performance overview.The bars show the price performance of ZEG.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20

ZEG.DE long term performance overview.The bars show the price performance of ZEG.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20

The current stock price of ZEG.DE is 144.35 EUR. In the past month the price increased by 11%. In the past year, price increased by 0.52%.

ASTRAZENECA PLC / ZEG Daily stock chart

ZEG.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 51.27 671.13B
LLY.DE ELI LILLY & CO 49.17 643.59B
JNJ.DE JOHNSON & JOHNSON 18.62 398.58B
1JNJ.MI JOHNSON & JOHNSON 18.54 396.89B
RHO.DE ROCHE HOLDING AG-BR 15.07 259.12B
1ROG.MI ROCHE HOLDING AG-GENUSSCHEIN 14.21 244.39B
1NOVN.MI NOVARTIS AG-REG 15.64 226.49B
NOT.DE NOVARTIS AG-REG 15.08 218.33B
SNW.DE SANOFI 11.47 211.00B
SAN.PA SANOFI 11.45 210.63B
1SAN.MI SANOFI 11.41 209.90B
NOV.DE NOVO NORDISK A/S-B 13.81 205.00B

About ZEG.DE

Company Profile

ZEG logo image AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.

Company Info

ASTRAZENECA PLC

1 Francis Crick Avenue, Cambridge Biomedical Campus

CAMBRIDGE CAMBRIDGESHIRE GB

Employees: 94300

ZEG Company Website

ZEG Investor Relations

Phone: 442073045000

ASTRAZENECA PLC / ZEG.DE FAQ

What is the stock price of ASTRAZENECA PLC today?

The current stock price of ZEG.DE is 144.35 EUR. The price decreased by -0.24% in the last trading session.


What is the ticker symbol for ASTRAZENECA PLC stock?

The exchange symbol of ASTRAZENECA PLC is ZEG and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is ZEG.DE stock listed?

ZEG.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for ASTRAZENECA PLC stock?

33 analysts have analysed ZEG.DE and the average price target is 154.88 EUR. This implies a price increase of 7.29% is expected in the next year compared to the current price of 144.35. Check the ASTRAZENECA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ASTRAZENECA PLC worth?

ASTRAZENECA PLC (ZEG.DE) has a market capitalization of 447.56B EUR. This makes ZEG.DE a Mega Cap stock.


How many employees does ASTRAZENECA PLC have?

ASTRAZENECA PLC (ZEG.DE) currently has 94300 employees.


What are the support and resistance levels for ASTRAZENECA PLC (ZEG.DE) stock?

ASTRAZENECA PLC (ZEG.DE) has a support level at 128.51 and a resistance level at 146.35. Check the full technical report for a detailed analysis of ZEG.DE support and resistance levels.


Is ASTRAZENECA PLC (ZEG.DE) expected to grow?

The Revenue of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 9.63% in the next year. Check the estimates tab for more information on the ZEG.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ASTRAZENECA PLC (ZEG.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ASTRAZENECA PLC (ZEG.DE) stock pay dividends?

ASTRAZENECA PLC (ZEG.DE) has a dividend yield of 1.95%. The yearly dividend amount is currently 2.56. Check the full fundamental report for a detailed analysis of ZEG.DE dividend history, reliability and sustainability.


When does ASTRAZENECA PLC (ZEG.DE) report earnings?

ASTRAZENECA PLC (ZEG.DE) will report earnings on 2025-11-06, before the market open.


What is the Price/Earnings (PE) ratio of ASTRAZENECA PLC (ZEG.DE)?

The PE ratio for ASTRAZENECA PLC (ZEG.DE) is 19.09. This is based on the reported non-GAAP earnings per share of 7.56 and the current share price of 144.35 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ZEG.DE.


ZEG.DE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE is one of the better performing stocks in the market, outperforming 74.02% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ZEG.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. ZEG.DE scores excellent on profitability, but there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZEG.DE Financial Highlights

Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 7.56. The EPS increased by 22.3% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.68%
ROA 7.38%
ROE 18.55%
Debt/Equity 0.63
Chartmill High Growth Momentum
EPS Q2Q%9.6%
Sales Q2Q%11.74%
EPS 1Y (TTM)22.3%
Revenue 1Y (TTM)15%

ZEG.DE Forecast & Estimates

33 analysts have analysed ZEG.DE and the average price target is 154.88 EUR. This implies a price increase of 7.29% is expected in the next year compared to the current price of 144.35.

For the next year, analysts expect an EPS growth of 13.74% and a revenue growth 9.63% for ZEG.DE


Analysts
Analysts81.82
Price Target154.88 (7.29%)
EPS Next Y13.74%
Revenue Next Year9.63%

ZEG.DE Ownership

Ownership
Inst Owners48.98%
Ins Owners0.04%
Short Float %N/A
Short RatioN/A